Lipton RB, et al. Patient Global Impression of Change related to improvement in most bothersome symptom following treatment with eptinezumab. IHC-PO-167. IHC 2019, 5-8 sept. Dublin, Ierland.
Ublituximab bij MS: 5-jaarsdata uit de open-label extensiestudie van ULTIMATE I en II
mei 2026 | Multipele Sclerose